CHEK1 and small cell lung carcinoma: Prior in vivo investigations have revealed that the application of poly ADP-ribose polymerase (PARP) inhibitors and checkpoint kinase 1 (CHK1) inhibitors can effectively obstruct the DDR pathway, which exhibits substantial activity in SCLC.